These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34358397)

  • 1. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus.
    Jung Y; Koo BK; Jang SY; Kim D; Lee H; Lee DH; Joo SK; Jung YJ; Park JH; Yoo T; Choi M; Lee MK; Kang SW; Chang MS; Kim W; Hwang GS;
    Liver Int; 2021 Dec; 41(12):2892-2902. PubMed ID: 34358397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Puri P; Daita K; Joyce A; Mirshahi F; Santhekadur PK; Cazanave S; Luketic VA; Siddiqui MS; Boyett S; Min HK; Kumar DP; Kohli R; Zhou H; Hylemon PB; Contos MJ; Idowu M; Sanyal AJ
    Hepatology; 2018 Feb; 67(2):534-548. PubMed ID: 28696585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
    Mouzaki M; Wang AY; Bandsma R; Comelli EM; Arendt BM; Zhang L; Fung S; Fischer SE; McGilvray IG; Allard JP
    PLoS One; 2016; 11(5):e0151829. PubMed ID: 27203081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects.
    Legry V; Francque S; Haas JT; Verrijken A; Caron S; Chávez-Talavera O; Vallez E; Vonghia L; Dirinck E; Verhaegen A; Kouach M; Lestavel S; Lefebvre P; Van Gaal L; Tailleux A; Paumelle R; Staels B
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3783-3794. PubMed ID: 28938455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
    Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
    Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
    Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease.
    Lake AD; Novak P; Shipkova P; Aranibar N; Robertson D; Reily MD; Lu Z; Lehman-McKeeman LD; Cherrington NJ
    Toxicol Appl Pharmacol; 2013 Apr; 268(2):132-40. PubMed ID: 23391614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Bile Acids as Biomarkers for Disease Diagnosis and Prevention.
    Qi L; Chen Y
    J Clin Endocrinol Metab; 2023 Jan; 108(2):251-270. PubMed ID: 36374935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
    Luo Y; Decato BE; Charles ED; Shevell DE; McNaney C; Shipkova P; Apfel A; Tirucherai GS; Sanyal AJ
    JHEP Rep; 2022 Jan; 4(1):100392. PubMed ID: 34977519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
    Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.
    Alam S; Gupta UD; Alam M; Kabir J; Chowdhury ZR; Alam AK
    Indian J Gastroenterol; 2014 Sep; 33(5):452-7. PubMed ID: 25023045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
    Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
    Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.